{"id":915,"date":"2009-12-01T12:05:00","date_gmt":"2009-12-01T11:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/bisphosphonat-osteonekrose-vor-gericht"},"modified":"2009-12-01T12:05:00","modified_gmt":"2009-12-01T11:05:00","slug":"bisphosphonat-osteonekrose-vor-gericht","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/bisphosphonat-osteonekrose-vor-gericht","title":{"rendered":"Bisphosphonat-Osteonekrose vor Gericht"},"content":{"rendered":"<p>Im September 2009 fand vor einem Geschworenengericht in Manhattan ein von Pharmaindustrie, Juristen und B\u00f6rsenanalysten viel beachteter Prozess statt, in dem es um Kieferosteonekrosen unter oraler Therapie mit dem Bisphosphonat Alendrons\u00e4ure (Fosamax\u00ae, Merck) ging (1). Fosamax\u00ae war nach seiner Markteinf\u00fchrung 1995 ein \u201eBlockbuster-Produkt\u201d und z\u00e4hlte \u2013 wohl nicht nur in den USA \u2013 zu den [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im September 2009 fand vor einem Geschworenengericht in Manhattan ein von Pharmaindustrie, Juristen und B\u00f6rsenanalysten viel beachteter Prozess statt, in dem es um Kieferosteonekrosen unter oraler Therapie mit dem Bisphosphonat Alendrons\u00e4ure (Fosamax\u00ae, Merck) ging (1). Fosamax\u00ae war nach seiner Markteinf\u00fchrung 1995 ein \u201eBlockbuster-Produkt\u201d und z\u00e4hlte \u2013 wohl nicht nur in den USA \u2013 zu den [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2337,145,256,2169,254,253],"class_list":["post-915","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alendronsaeure","tag-bisphosphonate","tag-nebenwirkungen","tag-osteonekrosen","tag-uaw","tag-unerwuenschte-arzneimittelwirkungen"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=915"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/915\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}